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15 Obesity and metabolic syndrome (MetS) are serious and
growing health care problems worldwide, leading an
increased risk for type 2 diabetes (T2D) and cardiovascu-
lar disease (CVD). Over the past decade, emerging
evidence has shown that an increased chromosomal
20 damage, as determined by the cytokinesis-block micronu-
cleus (CBMN) assay, is correlated to the pathogenesis of
metabolic and CVD. An increased micronuclei (MN)
frequency has been demonstrated in peripheral blood
lymphocytes of patients with polycystic ovary syndrome,
25 a common condition in reproductive-aged women associ-
ated with impaired glucose tolerance, T2D mellitus and the
MetS. High levels of MN have been detected to be
significantly correlated with T2D as well as with the
occurrence and the severity of coronary artery disease
30 (CAD). Long-term follow-up studies have shown that an
increased MN frequency is a predictive biomarker of
cardiovascular mortality within a population of healthy
subjects as well as of major adverse cardiovascular events
in patients with known CAD. Overall, these findings
35 support the hypothesis that CBMN assay may provide an
useful tool for screening of the MetS and its progression to
diabetes and CVD in adults as well in children. Large
population-based cohorts are needed in order to compare
the MN frequencies as well as to better define whether MN
40 is a biomarker or a mediator of cardiometabolic diseases.
Introduction
Cardiovascular disease (CVD) and type 2 diabetes (T2D) are
leading causes of morbidity and death in the Western society,
accounting for a great proportion of health care costs (1,2).
45 These diseases share common risk factors, including obesity,
insulin resistance, blood glucose, lipid oxidation toxicity and
low-grade inflammation, and they coexist in a great number of
patients.
The½AQ5 incidence of CVD, especially coronary heart disease
50 (CAD), and diabetes is increased in persons with the metabolic
syndrome (MetS), a cluster of metabolic abnormalities
including central obesity, hypertension and insulin resistance
(3). According½AQ6 to clinical criteria from a recent joint interim
statement of the Scientific Societies of diabetes and cardiology
55(3), any three of the five criteria reported in Table I are
diagnostic for the MetS. The MetS is a growing clinical and
public health problem worldwide, and it is reaching pandemic
proportions from the United States to Europe as well as in
developing countries, such as India and China (4). In these
60countries, an increasing number of adolescents and young
adults show signs of the MetS that may markedly affect the
incidence and prevalence of diabetes mellitus and CVD (4,5).
Indeed, it has been estimated that people with the MetS are at
twice the risk of developing CVD as compared with those
65without the syndrome and experience a 5-fold increased risk of
T2D (5).
T2D is the most common form of diabetes in humans,
affecting 95% of all diagnosed cases. The global number of
people with diabetes was 151 million in 2000, and it is
70projected to increase to 221 million in 2010 (an increase of
46%) both in developed and developing countries (6)
Accordingly, the epidemic of diabetes and its complications
confers major burdens of mortality, morbidity and health care
costs. T2D is characterised by an increased risk for the
75development of microvascular complications (neuropathy,
renal disease and retinopathy) and macrovascular disease
(coronary heart disease, cerebrovascular disease and peripheral
vascular disease). Coronary artery disease is the most common
complication and cause of morbidity and mortality in patients
80with T2D (6).
Furthermore, it is also important to note that there is
considerable evidence of an increased cancer risk in diabetic
patients, being more evident for primary liver cancer and
pancreatic cancer (7).
85Primary prevention is, thus, a fundamental strategy for
diminishing the overall burden of MetS, and the identification
of biomarkers for early detection and prognosis is of the utmost
importance in order to reduce the progression to T2D and CVD.
In recent years, the role of chromosomal instability,
90mediated by oxidative DNA damage and shortened dysfunc-
tional telomeres, in the pathogenesis of CVD and diabetes has
attracted a continuously growing research interest (8).
The cytokinesis-block micronucleus (CBMN) assay is the
most frequently used chromosomal biomarker in human
95lymphocytes in order to study genotoxicity and cytotoxicity
both in vitro and in vivo (9,10).
It ½AQ7is now well established that the CBMN assay in its
comprehensive ‘cytome’ mode provides simultaneous infor-
mation on chromosomal breakage, chromosome rearrange-
100ments and gene amplification as well as other critical events,
such as cell death (both apoptosis and necrosis) and cell
cytotoxicity (10).
Therefore, the CBMN assay may prove to be very useful in
the prediction and possibly the clinical management of chronic
105degenerative diseases, including diabetes and CVD.
The purpose of the present article is to review the current
knowledge concerning the application of CBMN test in the
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pathogenesis of cardiometabolic diseases as well as to discuss
the future research perspectives in order to elucidate the
110 prognostic power of micronuclei (MN) as biomarker for the
detection and the progression from MetS to T2D mellitus and
CVD.
Significant achievements
MN, obesity and MetS
115 Obesity is a main causative factor in the development of MetS
and is a growing worldwide problem. Recent estimates show
that in the USA, about a third of adults 20–74 years of age are
obese with body mass index (BMI)  30 and another third are
overweight (BMI 25.0–29.9) (11). Importantly, pediatric
120 obesity is also increasing at an alarming rate, highlighting the
importance of accurate, timely identification of metabolic
complications of obesity (12).
Obesity is a natural consequence of over nutrition and
sedentary lifestyle that dysregulates metabolic processes,
125 including action of insulin on glucose-lipid-free fatty acid
metabolism, blood glucose, blood pressure and lipids.
Obesity, particularly abdominal obesity, is a major risk
factor for MetS and plays a central role in the ‘insulin
resistance’, often leading to T2D mellitus and the development
130 of atherosclerotic CVD. The mechanisms responsible for
developing the MetS are not well known, but it is likely that
ectopic fat accumulation (such as visceral and hepatic fat
accumulation) and the pro-inflammatory state are central to the
development of insulin resistance and hyperinsulinemia.
135 In addition, chronic oxidative stress might be a major
mechanism underlying obesity-related co-morbidities (13).
Specifically, the inability to store fatty acids in subcutaneous
adipose tissue (14), and the expansion of abdominal fat
determine the exposure of body organs to an excessive flux of
140 free fatty acids (FFAs), which are known to affect insulin
signal transduction pathways, and induce endothelial dysfunc-
tion, due to increased reactive oxygen species (ROS)
generation and oxidative stress.
Prolonged release of FFAs is implicated in the development
145 diabetes since it promotes insulin resistance and the associated
loss of pancreatic beta-cell function (Figure 1).
Insulin resistance is also by itself a risk factor for CVD. It
blunts vascular production of nitric oxide, a factor that is
crucial to the normal vasodilatory response and endothelial
150 function.
Furthermore, visceral obesity is strongly associated with
high plasma triglycerides and low plasma high-density
lipoprotein-cholesterol, and with high plasma concentrations
of apolipoprotein B (apoB)-containing lipoproteins. The
155 generation of ROS, as the result of an imbalance between
tissue free radicals and antioxidants as well as of multiple by-
products of glucose and (pro)inflammatory molecules, may
also exert adverse effects on the DNA, contributing to the
initiation and progression of CVD and diabetes (8).
160Indeed, some studies have evidenced the association of
overweight and obesity with enhanced levels of different
indices of oxidants (13,15). In these studies, DNA damage
levels were significantly higher in both subjects with obesity
(16) and with MetS (17) than in normal subjects. Importantly,
165subjects showed a significant decreasing trend in total
antioxidant capacity levels and a significant increasing trend
in DNA damage values with the increase in the number of
metabolic disturbances (17).
However, there is yet very little information available on the
170association between MN levels, obesity and MetS. Recently,
several papers have demonstrated an association between
increased MN frequency and polycystic ovary syndrome
(PCOS) (18–20). PCOS is a complex endocrine condition
affecting 4–8% of women of reproductive age. Its primary
175manifestations are the reproductive complications of menstrual
dysfunction, infertility and hyperandrogenism and the meta-
bolic complications of insulin resistance, an increase in
cardiovascular risk factors and an increased risk of T2D
mellitus in conjunction with a high incidence of generalised
180and abdominal obesity (21).
It is noteworthy that elevated levels of genomic instability
(greater number MN and chromosome malsegregation) present
in women with PCOS was positively correlated with the BMI
and insulin resistance levels (17,18).
185MN and diabetes mellitus
Diabetes, termed ‘diabetes mellitus’ in clinical terminology, is
a serious and growing health care problem worldwide and is
associated with severe acute and chronic complications. Type 1
insulin-dependent diabetes accounts for only 5–10% of all
190diabetic patients and results from an absolute deficiency of
insulin caused by the destruction of insulin-secreting pancreatic
b-cells. T2D, which is the most prevalent form, explaining
90–95% of cases of diabetes mellitus, is characterised by
insulin resistance and relative insulin deficiency. In both type 1
195and T2D, chronic hyperglycaemia is the primary cause of the
clinical complications of the disease.
Table I. Diagnostic criteria for MetS defined by the presence of 3 risk
factors
Abdominal obesity (waist
circumference)
Men . 94 cm (European); .102 cm (USA)
Women . 80 cm (European); 88 cm (USA)
Elevated triglycerides 150 mg/dl (1.7 mmol/l)
Reduced HDL-C Men , 40 mg/dl (0.9 mmol/l)
Women , 50 mg/dl (1.1 mmol/l)
Elevated blood pressure 130 systolic blood pressure
85 mmHg diastolic blood pressure
High fasting glucose 100 mg/dl (5.6 mmol/l)
HDL-C, high-density lipoprotein-cholesterol.
Fig. 1. Schematic representation of progression and outcomes of the MetS.
HDL, high-density lipoprotein; VLDL, very low-density lipoprotein.
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Diabetic complications in target organs arise from chronic
elevations of glucose via increased production of ROS and
reactive nitrogen species and subsequent oxidative stress.
200 Excessive production of oxygen-free radicals through glucose
auto-oxidation and non-enzymatic glycation, especially in diabetic
patients with poor glycemic control, can accelerate oxidative
damage to the macromolecules, including DNA damage.
During the last years, increased oxidative DNA damage in
205 diabetes has been well documented, and it has been suggested
that it may be a useful clinical marker in order to predict
diabetic complications, such as microangiopathy and macro-
angiopathy (22–26). Interestingly, it has also been found that
oxidative DNA damage as observed in the comet assay was
210 higher in individuals with T2D mellitus as compared to those
with type-1 diabetes (25). As indicated in Figure 2, it is also
noteworthy that levels of oxidative DNA damage were
significantly more elevated in patients with CAD and
dyslipidemia or T2D (25).
215 Furthermore, DM is a strong determinant of chromosomal
DNA damage in both in type-1 diabetes mellitus and T2D (28–
31,27). Patients with type-1 diabetics showed a significantly
higher sister chromatid exchange frequency than healthy
subjects (28,30). In women of the Ludwigshafen Risk and
220 Cardiovascular Health study a high level of stable chromo-
somal aberrations in peripheral lymphocytes is associated with
T2D and directly correlated with the risk of early diabetes-
related death (29).
As regards MN assay, no significant difference was found in
225 MN frequency in type-1 diabetic patients as compared with
controls (30). On the contrary, significantly high levels of MN
frequency were found in patients with type 2 with no
microvascular or macrovascular complications (31). In a large
population of patients undergoing coronary angiography, we
230found that T2D was the major independent determinant of an
increased MN frequency in circulating lymphocytes of patients
with ischemic heart disease (27). We have also shown that
diabetes was a significant determinant of MN levels, even
when the patients were stratified according to the presence of
235CAD (Figure 2).
Recently, Zu´n˜iga-Gonza´lez et al. (32) demonstrated that either
controlled (glycosylated haemoglobin levels ,7%) or un-
controlled diabetic patients (glycosylated haemoglobin levels
.7%) had 2-fold higher frequency of MNs in buccal mucosa
240samples than healthy subjects. There was also evidence of an
increased MN frequency among patients with uncontrolled type
1 diabetes as compared with patients with a good metabolic
control. Furthermore, a significant reduction in MN was
observed after folate supplementation for 30 days (32).
245MN and CVD
The American Heart Association reports that CVD is the
dominant health problem in the Western Society (1) and is
expected to be the number one cause of death worldwide in
2020 (2).
250Major clinical manifestations of CVD include myocardial
infarction, coronary artery disease, stroke, peripheral artery
disease and congestive heart failure. In most cases, these
clinical conditions result from atherosclerosis, a progressive
and inflammatory disease of the arterial wall, characterised by
255focal thickening and luminal obstruction (33).
Fig. 2. Diabetes is a strong determinant of chromosomal and oxidative DNA damage in patients with ischemic heart disease as measured by comet assay and CBMN
assay. [Figure adapted from references (25) and (27); statistical differences were evaluated by Student’s t-test after the logarithmic transformation of data].
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At the present time, there is consistent evidence supporting
the notion that oxidative stress-induced-genetic instability is
a relevant contributor of atherosclerotic plaque development
and its acute complications (34–36).
260 Indeed, DNA damage is present in human atherosclerotic
plaque ranging from ‘macro’ damage, including deletions or
additions of whole chromosomes or parts of chromosomes to
‘micro’ damage which includes loss of heterozygosity and
microsatellite instability (mutations in DNA regions that may
265 affect gene expression), DNA strand breaks and modifications
of DNA (including oxidation) or DNA adducts (37–46).
Specifically, the existence of chromosomal aneuploidy in
multinucleated endothelial cells may be important in athero-
genesis by strongly expressing low-density lipoproteins (LDL)
270 receptors and increasing LDL uptake to the subendothelial
intima (38). Chromosomal aberrations can also occur in
vascular smooth muscle cells of human atherosclerotic plaques,
especially in unstable plaques (37,39).
Human plaques show markers of oxidative damage, including
275 DNA strand breaks and oxidative modification of guanine
residues in DNA (45). Interestingly, DNA strand breaks,
oxidised pyrimidines and altered purines are also significantly
higher in leukocytes of patients with CAD, and DNA strand
breaks levels are higher in patients with acute coronary
280 syndrome as compared with patients with stable CAD (47).
During the last years, our group and others have demon-
strated the presence of chromosomal damage in circulating
cells of patients with CAD using the CBMN assay (48,49). In
these studies, an elevated frequency of MNs was significantly
285 correlated with both the occurrence (48,49) and the severity of
coronary artery disease (48). Furthermore, it is also important
to note that further chromosomal DNA damage is produced
in the peripheral lymphocytes of patients undergoing repeated
X-rays medical investigations and chronically administered
290 drugs, such nitrate therapy (27,50,51).
Finally, recent evidences have emphasised that both micro-
nutrient deficiencies and genetic variations in enzymes involved in
homocysteine (Hcy) metabolism may contribute to an increased
risk for CAD (34). In fact, hyperhomocysteinemia has been
295 identified as an independent risk factor for cerebral, coronary and
peripheral atherosclerosis, although the pathological mechanism
of this risk is not fully understood (34). High levels of Hcy have
been also reported to be an increased risk factor for neural defects,
Alzheimer’s disease and loss of cognitive functions (52).
300 Accordingly, it is interesting to note that C677T poly-
morphism within the 5,10-methylenetetrahydrofolate reductase
gene and the levels of plasma Hcy and vitamin B12 are
important determinants of MN frequency in patients with
CAD, supporting the hypothesis that pathways of folate
305 metabolism may be a risk factor for atherosclerosis by
influencing genomic stability (53).
MN and clinical follow-up
Recently, we also validated the predictive value of MN in
peripheral blood lymphocytes for clinical outcome of CVDs.
310 The cytogenetic monitoring, carried out in 1991–93 on 1650
healthy subjects, and aimed to define some reference biological
parameters of a ‘normal population’ to be used as a control for
further analysis, gave us the opportunity to carry out a nested
case–control study (54). The surviving status, or the cause of
315 death, was monitored for all subjects until January 2005. At the
end of the follow-up, 111 deaths were recorded and 39 deaths
for CVD cases were observed. A significantly higher MN
frequency observed at the time of the recruitment in the CVD
group was found in comparison with the control group (54).
320The Kaplan–Meier analysis demonstrated a significantly
shorter survival for CVD for subjects with a higher MN
frequency as compared to subjects with a lower frequency
(Figure 3).
Finally, our findings indicate that MN levels are the
325significant predictors of future cardiovascular events in patients
with known CAD.
In a long-term follow-up prospective study of 178
consecutive patients, we assessed the relationship between
tertiles of MN and the risk of major adverse cardiovascular
330events (cardiac death, myocardial infarction, stroke, congestive
heart failure, unstable angina, coronary and peripheral
revascularization). After a mean follow-up of four years, we
found that the overall event-free survival was 77.5, 70.4 and
49.0% in patients with the low, medium and upper tertiles of
335MN, respectively (Figure 3). We found that patients in the
upper tertile had a 2.2-fold increased risk of developing adverse
cardiac events (55).
Important knowledge gaps
Overall, these studies indicate that an increased MN frequency
340is correlated to the pathogenesis of metabolic and CVD
(Table II). The results support the hypothesis that the CBMN
assay may expand the prognostic power of established
biomarkers for the detection and the progression from MetS
to T2D mellitus and CVD.
345Despite the findings from prior studies, many gaps in
knowledge currently exist in our understanding of the
association between elevated MN frequency and adverse
outcomes in patients with cardiometabolic disorders.
Fig. 3. Kaplan–Meier curves showing cumulative rates of survival for
cardiovascular mortality within a population of healthy subjects (a) and for
major adverse cardiovascular events in patients with known CAD (b)
according to the levels of MN. [Figure adapted from references (54) and (55)].
M. G. Andreassi et al.
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One of the most important gaps is the question as to whether
350 MN is an independent cardiometabolic risk factor or only
a surrogate of the chronic oxidative stress and/or inflammation.
Indeed, more and more evidence suggests that telomere
shortening associated with chromosome instability may be key
determinants to the pathogenesis of cardiometabolic diseases by
355 inducing premature vascular senescence (8). Telomeres are,
indeed, necessary for the genomic stability and integrity,
preventing chromosomal fusion by cellular DNA repair pro-
cesses. Progressive telomere shortening has been demonstrated
in peripheral blood cells from patients with MetS, diabetes
360 mellitus, CAD and premature myocardial infarction (8).
It is interesting to note in this context that a recent report
reported a significant correlation between telomere shortening
and MN frequency (56). These data support the hypothesis that
the levels of genetic instability (blood telomere length and MN)
365 may be useful biological markers for cardiometabolic diseases.
However, the role of both telomere shortening and
chromosomal damage remains a poorly understood process in
the pathogenesis of cardiometabolic disease. Thus, establishing
conclusively whether genetic instability plays a causative role
370 in vascular dysfunction still remains to be established.
Particularly, an important knowledge gap is clarifying the
relationship in humans between MN frequency in lymphocytes
and that in cells of the vascular wall, such as endothelial cells.
Moreover, a better understanding of the association between
375 MN and cardiometabolic disease need to carefully consider
a series of clinical and confounding factors such as the quality
of the metabolic control, the type of diabetes, the duration of
the disease, the influence of genetic polymorphisms, the drugs
and radiation imaging treatment used for therapy. To gain more
380 insights in the role of MN in cardiometabolic disease, we also
need large population-based cohorts with MN and the
associated nucleoplasmic bridge and nuclear bud biomarker
measurement at multiple time-points.
A coordinated effort involving multiple centers is warranted
385 in order to compare the MN frequencies as well as to better
define whether MN is a biomarker or a mediator of
cardiometabolic diseases.
Concluding remarks and future work
Increasing burdens of obesity, MetS and T2D require pre-
390 ventive and therapeutic interventions against these conditions
and the accompanying CVD risk. In the clinical practice, there
is the need for easy, not expensive and safe biomarkers for the
early detection of diseases and also to identify high-risk
subjects who might benefit from increased screening
395surveillance.
The simplicity, rapidity and sensitivity of the CBMN assay
may provide an useful tool for screening of the MetS in adults
as well as in children. In order to explore this potential, further
studies are needed to investigate in more depth what is the role
400of MN in predicting the risk of these diseases, especially of
diabetes, since there is no previous record. Specifically, there is
a need for prospective studies to establish whether increased
MN frequency appears to be related to ‘lifestyle diseases’,
which are associated with hypernutrition and lack of exercise,
405and are characterised by metabolic abnormalities, i.e. primarily
insulin resistance and obesity.
Clinical research must seek to define whether MN frequency
can be prevented by tight control of blood glucose, pressure
and lipids and/or by caloric restriction, improvement in
410physical fitness and antioxidant supplementation.
This point is of particular interest in relation to evidence
showing that a range of healthy lifestyle factors, including
exercise, are associated significantly with reduced MN
frequency (57).
415According to recent evidence, supporting the fascinating
concept that the MetS may originate in utero (58,59), further
studies should also determine the impact of maternal over
nutrition and diet composition on MN frequency of the foetus
and newborns. The evaluation of chromosomal damage can be
420an important pathogenetic factor and an additional prognostic
predictor—evaluating a biologic dimension presently ignored
by the current stratification of risk—and a potential target of
therapeutic intervention ½AQ8.
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